WO2014150935A1 - Method and products for enhancing drug and dietary supplement bioavailability - Google Patents

Method and products for enhancing drug and dietary supplement bioavailability Download PDF

Info

Publication number
WO2014150935A1
WO2014150935A1 PCT/US2014/024592 US2014024592W WO2014150935A1 WO 2014150935 A1 WO2014150935 A1 WO 2014150935A1 US 2014024592 W US2014024592 W US 2014024592W WO 2014150935 A1 WO2014150935 A1 WO 2014150935A1
Authority
WO
WIPO (PCT)
Prior art keywords
dietary
family
drug
dietary supplement
supplement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/024592
Other languages
English (en)
French (fr)
Inventor
Daryl L. BARNETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBA Pharma Inc
Original Assignee
CBA Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBA Pharma Inc filed Critical CBA Pharma Inc
Priority to JP2016501583A priority Critical patent/JP2016514142A/ja
Priority to MX2015013158A priority patent/MX2015013158A/es
Priority to KR1020157029730A priority patent/KR20150143504A/ko
Priority to CN201480028482.XA priority patent/CN105357966A/zh
Priority to EP14767625.8A priority patent/EP2986122A4/en
Publication of WO2014150935A1 publication Critical patent/WO2014150935A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Bioavailability for dietary supplem ns is sml r, aud A generally defned as the proportion of the ad ⁇ aistered s bslanoe capable of bei g absorbed nd available for use or storage, to both pharmacology and nuuition sciences, bioavadasenty Is meassupsd by calculating the arcs uader tbe curve (AU €> o 3 ⁇ 4e drug or dietary sup lement nceotradon lime profile.
  • Wher Rs am! i f are the same r different shostc ained carbo ased llgaod deluding without limtation CI! ⁇ €(>:>£!3 ⁇ 4 or U; d 3 ⁇ 4 is C3 ⁇ 4 or ' C2H3; and !v. s O E or hydmgsre d where the chem al a uctore lias the "S" i3 ⁇ 4>m «ri;c coagulati n at the ( 1 " chlrai csrfeon !oeMkm,
  • Sf Drugs & dietary au pieoioots are adsorbed through, fbe liolog of the alkacrstary ca al at dif!breot rates.
  • the oxieol t ich cooeorrent admioiatrahoo. of a d-telraodri3 ⁇ 4o fomify me b r enhooees the & mi md rate of soeb sra tioo will .also vary accordingly.
  • Those drugs and dietary- su leme ts with mpM d approaches complete rates of adsorption ma show little or no im rovetoera i bloadsorptsoa ara!
  • T3 ⁇ 4e -tetiamki e family member ami the drag or dietary soppleme t caa-fee foramlated toge&er kites a sm$de formula, they oaa bo tbra ⁇ u!sied separately aad adodmoiered sdher sroiihrnjie oaly sofBc ody close together thai they are boft m.
  • drag or dietary ao leioeai will vary from p réelleit to padeot aod as a i oohosi of the priocipk drug.
  • -or dteimy supplement used o lhin a raege of from about 0.04:1 to shoot 170:1.
  • a rnt typical rnge woak! he imm. about 1:1 to 100: 1, more preferabl !ror .25:75 to 75:25.
  • the dosage l el £1 ⁇ 2 hhe d-tebarKlnoe family member will vary fern case to eae, based an the patieot ai3 ⁇ 4s
  • ⁇ cm exist h ⁇ the tree base forn r 3 ⁇ 4s a mono or di-acid sab. Because of the enhanced solubility of the salt form of p rmae3 ⁇ 4 tleal mgredlems, the sab forms ar used, m brmibadng h maeeiaie i c>m os3 ⁇ 4ons.
  • the ⁇ active baeredieai bras solebitizes more qoieb!y and ertters sh 'bloodstream fmi&x.
  • the free base form h not soluble is water. Ho ever, it has .recently been surprisingly fours!
  • tbe free base form lations of d ⁇ irmm family member are absobed, into- the bloodstream sabsbmilai!y asTa dl as Ibrmelabons of the- dl-aeid salt m m es ⁇ the famiy, Acc rdingl ., vee pro ose to use either die free base or tbe di-aaid salt of the d-;ao ndnoe tbnilhy member ie oar ibmnuatioos.
  • P01@J T3 ⁇ 4e preferred formalatiorss comprise & mem e of tbe d-ietrandtbve family combined with a preparationabte phMirscea& f carrier.
  • the p tnToaeeutioal carrie ears be a liquid, or a. solid composition
  • a liquid carrier will preferably comprise water, possibly with additional lagredieois sued as ,25%
  • the solid carrier or dlu nt ' used be pregekinked.
  • starch mforoerystatlme eelkbose or the like, !t raay also be !brraolaied with other ingre ents, such as colloidal silicone dioxide, sodium lauryl sulfate and mag sx siear ie.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
PCT/US2014/024592 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability Ceased WO2014150935A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2016501583A JP2016514142A (ja) 2013-03-15 2014-03-12 薬物及び栄養補助剤のバイオアベイラビリティを高める方法及び生成物
MX2015013158A MX2015013158A (es) 2013-03-15 2014-03-12 Metodo y productos para mejorar la biodisponibilidad de los farmacos y de los suplementos dieteticos.
KR1020157029730A KR20150143504A (ko) 2013-03-15 2014-03-12 약물 및 영양 보조식품의 생체이용률을 증진시키기 위한 방법 및 생성물
CN201480028482.XA CN105357966A (zh) 2013-03-15 2014-03-12 提高药物和膳食补充剂的生物利用度的方法和产品
EP14767625.8A EP2986122A4 (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792700P 2013-03-15 2013-03-15
US61/792,700 2013-03-15

Publications (1)

Publication Number Publication Date
WO2014150935A1 true WO2014150935A1 (en) 2014-09-25

Family

ID=51529972

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024592 Ceased WO2014150935A1 (en) 2013-03-15 2014-03-12 Method and products for enhancing drug and dietary supplement bioavailability

Country Status (7)

Country Link
US (1) US9345257B2 (enExample)
EP (1) EP2986122A4 (enExample)
JP (1) JP2016514142A (enExample)
KR (1) KR20150143504A (enExample)
CN (1) CN105357966A (enExample)
MX (1) MX2015013158A (enExample)
WO (1) WO2014150935A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2986122A4 (en) 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing drug and dietary supplement bioavailability
JP2016514143A (ja) * 2013-03-15 2016-05-19 シービーエー・ファーマ・インコーポレイテッドCba Pharma, Inc. 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20070027181A1 (en) * 2004-08-03 2007-02-01 Education Center Of Traditional Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
EP2986122A4 (en) 2013-03-15 2017-01-18 CBA Pharma Inc. Method and products for enhancing drug and dietary supplement bioavailability
JP2016514143A (ja) * 2013-03-15 2016-05-19 シービーエー・ファーマ・インコーポレイテッドCba Pharma, Inc. 薬物及び栄養補助剤の細胞取り込みを高める方法及び生成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US20070027181A1 (en) * 2004-08-03 2007-02-01 Education Center Of Traditional Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JIA WEI, SYNERGISTIC INTERACTION BETWEEN TETRANDRINE AND CHEMOTHERAPEUTIC AGENTS AND INFLUENCE OF TETRANDRINE ON CHEMOTHERAPEUTIC AGENT-ASSOCIATED GENES IN HUMAN GASTRIC CANCER CELL LINES
LIEBERMAN, SYNERGY BETWEEN TETRANDRINE AND FK506 IN PREVENTION OF DIABETES IN BB RATS
See also references of EP2986122A4 *
SHI JIAN-PING, SYNERGISTIC EFFECTS OF TETRANDRINE ON THE ANTIFUNGAL ACTIVITY OF TOPICAL KETOCONAZOLE CREAM IN THE TREATMENT OF DERMATOPHYTOSES
YOUNG-SEOB LEE, SYNERGISTIC EFFECT OF TETRANDRINE AND ETHIDIUM BROMIDE AGAINST MRSA

Also Published As

Publication number Publication date
EP2986122A4 (en) 2017-01-18
US20140275140A1 (en) 2014-09-18
JP2016514142A (ja) 2016-05-19
MX2015013158A (es) 2016-04-15
CN105357966A (zh) 2016-02-24
EP2986122A1 (en) 2016-02-24
US9345257B2 (en) 2016-05-24
KR20150143504A (ko) 2015-12-23

Similar Documents

Publication Publication Date Title
ES2638517T3 (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
HRP20151337T1 (hr) Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil- ili n,n-dimetil)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin
HRP20140569T1 (hr) Derivati cis-tetrahidro-spiro(cikloheksan-1,1'-pirido[3,4-b]indol)-4-amina
JP2013505205A5 (enExample)
JP2015515475A5 (enExample)
WO2007108990A3 (en) Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
JP2012533565A5 (enExample)
MX2009007784A (es) Composiciones de tiacumicinas estables.
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
EP2986122A1 (en) Method and products for enhancing drug and dietary supplement bioavailability
RU2008134874A (ru) Способ увеличения сухой мышечной массы и уменьшения жировой ткани
CA2648518A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
NZ630494A (en) Administration of lorcaserin to individuals with renal impairment
WO2012064159A3 (ko) 항암용 조성물
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
JP2007508298A5 (enExample)
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
WO2020068657A8 (en) 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
FI3144002T3 (fi) Granulosyytti-makrofagikasvutekijää (GM-CSF) tuottava T-solusäätelyaine sekä Th1/Th2-immuunitasapainon säätelijä
RU2008129615A (ru) Комбинация агониста 5-ht4 и ингибитора холинэстеразы
RU2012136190A (ru) Фармацевтический состав для профилактики или лечения артрозоартрита, содержащий ребамипид в качестве активного ингредиента
HRP20171922T1 (hr) Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano [3,4,b]indol]-4-amin i duloksetin
WO2011035343A3 (en) Phentermine liquid dosage form

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480028482.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14767625

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016501583

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/013158

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2014767625

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20157029730

Country of ref document: KR

Kind code of ref document: A